



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostics.com

Date: November 14, 2025

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN
ISIN: INE0B2N01016

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Outcome of Board meeting held on Friday, November 14, 2025, at 04:30 P.M. (IST)

Dear Sir/Madam,

In compliance with Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), this is to inform your good office that the Board of Directors of the Company at their meeting held on Friday, November 14, 2025, has, inter alia, considered and approved the following items of agenda:-

(a) Taken on record the Limited Review Report for Un-audited Financial Results (Standalone and Consolidated) of the Company for the half year ended September 30, 2025, and

(b) Taken on record the certificate for utilization of funds issued by the Statutory Auditor of the company.

Further, pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and our communication letter dated September 25, 2025, the trading window for dealing in securities of the Company had already been closed for Designated Person(s), Connected Person(s) and their immediate relative(s) with effect from October 01, 2025 and shall re-open after the expiry of 48 hours from the aforesaid un-audited Financial Results for second and half year ended September 30, 2025 generally made available to the public.

The Board meeting commenced at 04:30 PM and concluded at 10:50 P.M.

Kindly take the above information on record. The above information is also available on the Company's website at www.chandandiagnostics.com.

Thanking you,

Yours sincerely,

For Chandan Healthcare Limited

Rajeev Kumar Nain
Company Secretary & Compliance Officer

Encl.: as above



MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor' Review Report on the Half Yearly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of M/s. *Chandan Healthcare Limited* ("the Company"), for the half year ended September 30, 2025, for the period April 1, 2025 to September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting", prescribed under Section 133 the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



: **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.



: **Branch Office:** - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.



: **CA Saurabh Tyagi:** 7718802884, **CA Navodit Tyagi:** 9167436404, **CA Manoj Modi:** 9022059201.



: saurabh@msnt.in navodit@msnt.in manoj@msnt.in

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the applicable Accounting Standard prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322


Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 25533375BMOKOF3591

Place: Noida

Date: 14th Nov,2025



COMPANY NAME :- Chandan Healthcare Limited
CIN :- L85110UP2003PLC193493
REGISTERED ADDRESS :- Biotech Park, Sector G, Kurai road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Standalone Statement of Financial Results for the half year ended 30th Sept, 2025

Particulars	Half Year Ended		Year Ended	
	30th Sept, 2025	31st March, 2025	30th Sept, 2024	31st March, 2024
I. Revenue from operations	Unaudited	Unaudited	Unaudited	Audited
II. Other income	7,617.93	6,716.54	6,199.88	12,916.42
	145.10	68.14	62.89	131.03
III. Total revenue(=I+II)	7,763.03	6,784.67	6,262.78	13,047.45
IV. Expenses:				
Cost of material consumed	1,353.98	801.94	740.25	1,542.19
Purchase of stock-in-trade	265.18	232.24	214.37	446.61
Change in inventories of finished goods, work-in-progress and stock-in-trade.	38.25	(9.97)	(9.21)	(19.18)
Employee benefits expense.	1,694.73	1,736.05	1,602.51	3,338.56
Finance Costs	211.80	185.55	171.28	356.83
Depreciation and amortisation expense	480.76	333.96	308.28	642.24
Other expenses	1,754.26	2,040.30	1,883.35	3,923.66
Total expenses (IV)	5,798.96	5,320.07	4,910.83	10,230.91
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	1,964.07	1,464.61	1,351.94	2,816.54
VI. Exceptional items	-	-	-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)	1,964.07	1,464.61	1,351.94	2,816.54
VIII. Extraordinary items	-	-	-	-
IX. Profit/(loss) before tax (VII- VIII)	1,964.07	1,464.61	1,351.94	2,816.54
X. Tax expense of continuing operation:-				
Current tax	436.96	364.07	336.07	700.14
Deferred tax	70.95	20.08	18.53	38.61
Tax expense(X)	507.91	384.15	354.60	738.75
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)	1,456.16	1,080.46	997.34	2,077.79
XII. Profit/(loss) from discontinuing operations	-	-	-	-
XIII. Tax expense of discontinuing operations	-	-	-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV. Share of (profit)/ loss transferred to minority interest	-	-	-	-
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	1,456.16	1,080.46	997.34	2,077.79
XVII. Earnings per equity share:				
(1) Basic	5.96	5.25	4.85	10.10
(2) Diluted	5.96	5.25	4.85	10.10

For & on behalf of the board of directors

Chandan Healthcare Limited

Amrit Singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 14th Nov, 2025

Asmita Singh

Managing director

Din. :- 01098055

Place :- Lucknow

Date :- 14th Nov, 2025

Rajeev Nain

CFO & Company secretary

Place :- 14th Nov, 2025

Date :- Lucknow

As per our report of even date attached
For M/s. MSNT & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322
Navodityagi
Partner
Membership no. :- 533375
UDIN no. :- 2553375BMOKOF3591
Place :- Noida
Date :- 14th Nov, 2025



COMPANY NAME :- Chandan Healthcare Limited

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Standalone Statement of Assets & Liabilities as at 30th Sept, 2025

Particulars	Figures as at the end of 30th Sept, 2025	Figures as at the end of 31st March, 2025
I. EQUITY AND LIABILITIES		
(1) Shareholder's funds		
(a) Share capital	2,445.21	2,445.21
(b) Reserves and surplus	11,082.56	9,626.40
(c) Money received against share warrants	-	-
(2) Share application money pending allotment	-	-
(3) Minority interest	-	-
(4) Non-current liabilities		
(a) Long-term borrowings	2,656.16	2,214.46
(b) Deferred tax liabilities(net)	261.28	190.33
(c) Other long-term liabilities	2.20	2.45
(d) Long term provisions	167.67	313.01
(5) Current liabilities		
(a) Short-term borrowings	2,461.27	1,105.92
(b) Trade payables		
(i) Total outstanding dues of micro & small enterprises.	430.44	662.44
(ii) Total outstanding dues of creditors other than micro & small enterprises.	517.88	371.54
(c) Other current liabilities	900.76	829.62
(d) Short term provisions	18.57	65.11
TOTAL	20,944.00	17,826.49
II. ASSETS		
(1) Non- current assets		
(a) Property, plant & equipments & intangible assets		
(i) Property, plant & equipments	8,607.55	7,148.48
(ii) Intangible assets	-	-
(iii) Capital work in progress	516.47	410.12
(iv) Intangible assets under development	-	-
(b) Non-current investments	4,866.70	2,598.61
(c) Deferred tax assets(net)	-	-
(d) Long -term loans and advances	53.90	76.39
(e) Other non-current assets	382.23	168.57
(2) Current assets		
(a) Current investments	-	1,059.00
(b) Inventories	1,543.73	1,711.99
(c) Trade receivables	2,751.73	3,267.17
(d) Cash and bank balances	1,654.32	603.10
(e) Short-term loans and advances	537.95	740.49
(f) Other current assets	29.42	42.57
TOTAL	20,944.00	17,826.49

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322

Navodit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKOF3591

Place :- Noida

Date :- 14th Nov,2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar singh Asmita singh
Managing director Managing director

Din. :- 01096328 Din. :- 01098055

Place :- Lucknow Place :- Lucknow

Date :- 14th Nov,2025 Date :- 14th Nov,2025

Rajeev Nain

CFO & Company secretary

Place :- 14th Nov,2025

Date :- Lucknow

COMPANY NAME :- Chandan Healthcare Limited

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Standalone Statement of Cash flow for the half year ended 30th Sept, 2025

Particulars	Figures for the half year ended 30th Sept, 2025	Figures for the year ended 31st March, 2025
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	1,964.07	2,816.54
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	480.76	642.24
Bad Debts & Balances written off/written back	3.88	(82.47)
Re-measurement (gains) / loss on defined benefit plans	(190.13)	71.77
Provision for doubtful debts	(18.72)	15.28
Provision for obsolete inventories	15.21	10.10
Non operating transactions		
Interest on borrowing	211.80	356.84
Interest income	(146.91)	(45.32)
Dividend income	-	-
Operating profit/(loss) before working capital changes	2,319.96	3,784.97
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	153.05	(1,076.28)
(Increase) / Decrease in trade receivables	530.28	(878.23)
(Increase) / Decrease in other current assets	24.52	(581.41)
(Decrease) / Increase in trade payables	(85.66)	421.94
(Decrease) / Increase in other current liabilities	140.09	(532.68)
Net cash (used in) / generated from operating activities	3,082.24	1,138.31
Income taxes refund / (paid), net	(507.91)	(738.75)
Net cash flow from operating activities(A)	2,574.33	399.56
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(2,046.18)	(3,848.04)
Sale/(Purchase) of non current & current investments	(1,209.09)	(2,029.73)
Interest income	146.91	45.32
Dividend income	-	-
Net cash flow from investing activities(B)	(3,108.36)	(5,832.45)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital	-	6,227.13
Proceeds from/(Payment of) long term & short term borrowings	1,797.05	412.54
Finance cost paid (including processing fees)	(211.80)	(356.84)
Dividend paid	-	(300.00)
Net cash flow from financing activities(C)	1,585.25	5,982.83
Net increase/decrease in cash or cash equivalents(A+B+C)	1,051.22	549.94
Cash and cash equivalents at the beginning of the period	603.09	53.15
Cash and cash equivalents at the end of the period	1,654.31	603.09

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants

Navodit tyagi
Partner
Membership no. :- 533375
UDIN no. :- 25533375BMOKOF3591
Place :- Noida
Date :- 14th Nov,2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 14th Nov,2025

Asmita singh
Managing director
Din. :- 01098055
Place :- Lucknow
Date :- 14th Nov,2025

Rajeev Nain
CFO & Company secretary
Place :- 14th Nov,2025
Date :- Lucknow



MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Independent Auditor' Review Report on the Half Yerly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to,
The Board of Directors,
Chandan Healthcare Limited,
Lucknow

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of M/s. *Chandan Healthcare Limited* ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the half year ended September 30, 2025 and for the period April 1, 2025 to September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Head Office: - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.



Branch Office: - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.



CA Saurabh Tyagi: 7718802884, **CA Navodit Tyagi:** 9167436404, **CA Manoj Modi:** 9022059201.



saaurabh@msnt.in navodit@msnt.in manoj@msnt.in

4. The Statement includes the results of the following entities:
- Chandan Pharmacy Limited.
 - Chandan Diagnostic Limited.
 - Indira Diagnostic Centre & Blood Bank Limited.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard specified under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We have reviewed the interim financial results of **Chandan Pharmacy Limited**, which is included in the Statement. We have not, however, reviewed the interim financial results of the other subsidiaries included in the Statement, namely **Chandan Diagnostic Limited** and **Indira Diagnostic Centre & Blood Bank Limited**. These interim financial results have been reviewed by other auditors, and their reports have been furnished to us by the Management. Our conclusion on the Statement, insofar as it relates to the amounts and disclosures pertaining to these two subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter.

For & On Behalf Of

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322


Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 25533375BMOKOE8591

Place: Noida

Date: 14th Nov,2025



COMPANY NAME :- Chandan Healthcare Limited
CIN :- L85110UP2003PLC193493
REGISTERED ADDRESS :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Consolidated Statement of Financial Results for the half ended 30th Sept, 2025

Particulars	Half Year Ended				Year Ended	
	30th Sept, 2025		31st March, 2025		31st March, 2025	31st March, 2024
	Unaudited		Unaudited		Audited	Audited
I. Revenue from operations	13,580.34		11,966.28		23,012.08	17,659.01
II. Other income	168.94		106.67		205.14	122.18
III. Total revenue (I+II)	13,749.28		12,072.95		23,217.22	17,781.19
IV. Expenses:						
Cost of material consumed	1,363.85		803.86		1,545.88	1,107.69
Purchase of stock-in-trade	5,607.77		4,939.03		9,498.14	7,241.77
Change in inventories of finished goods, work-in-progress and stock-in-trade.	(82.74)		(146.81)		(282.32)	(264.47)
Employee benefits expense.	1,862.48		2,020.78		3,886.11	3,542.40
Finance Costs	279.95		237.92		457.53	275.23
Depreciation and amortisation expense	492.90		350.73		674.48	340.40
Other expenses	1,899.53		2,200.08		4,230.88	3,392.10
Total expenses (IV)	11,523.74		10,405.59		20,010.70	15,635.12
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	2,225.54		1,667.36		3,206.52	2,146.07
VI. Exceptional items	-		-		-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)	2,225.54		1,667.36		3,206.52	2,146.07
VIII. Extraordinary items	-		-		-	-
IX. Profit/(loss) before tax (VII-VIII)	2,225.54		1,667.36		3,206.52	2,146.07
X. Tax expense of continuing operation:-						
Current tax	498.50		431.90		830.58	510.56
Deferred tax	76.29		12.66		24.34	(0.07)
Tax expense (X)	574.79		444.56		854.92	510.49
XI. Profit/(loss) for the period from continuing operations (after tax) (IX-X)	1,650.75		1,222.81		2,351.60	1,635.56
XII. Profit/(loss) from discontinuing operations	-		-		-	-
XIII. Tax expense of discontinuing operations	-		-		-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-		-		-	-
XV. Share of (profit)/ loss transferred to minority interest	(90.61)		(69.90)		(134.43)	(7.85)
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	1,560.14		1,152.90		2,217.17	1,627.73
XVII. Earnings per equity share:						
(1) Basic	6.38		5.60		10.78	8.14
(2) Diluted	6.38		5.60		10.78	8.14

As per our report of even date attached
For M/s Msmt & Associates LLP
Chartered accountants
Firm registration no. :- 018542C/C400322



Navodit tyagi
Partner
Membership no. :- 533375
UDIN no. :- 25533375BMOKOE8591
Place :- Noida
Date :- 14th Nov, 2025

For & on behalf of the board of directors
Chandan Healthcare Limited

Amir singh
Managing director
Din. :- 01096328
Place :- Lucknow
Date :- 14th Nov, 2025

Asmita Singh
Managing director
Din. :- 01098055
Place :- Lucknow
Date :- 14th Nov, 2025

Rajeev Nain
CFO & Company secretary
Place :- 14th Nov, 2025

COMPANY NAME :- Chandan Healthcare Limited

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Consolidated Statement of Assets & Liabilities as at 30th Sept, 2025

Particulars	Figures as at the end of 30th Sept, 2025	Figures as at the end of 31st March, 2025
I. EQUITY AND LIABILITIES		
(1) Shareholder's funds		
(a) Share capital	2,445.21	2,445.21
(b) Reserves and surplus	11,375.24	9,815.18
(c) Money received against share warrants	-	-
(2) Share application money pending allotment	-	-
(3) Minority interest	471.16	380.45
(4) Non-current liabilities		
(a) Long-term borrowings	2,656.16	2,214.46
(b) Deferred tax liabilities(net)	248.58	172.29
(c) Other long-term liabilities	2.20	2.45
(d) Long term provisions	186.75	343.69
(5) Current liabilities		
(a) Short-term borrowings	4,018.98	2,601.92
(b) Trade payables		
(i) Total outstanding dues of micro & small enterprises.	1,183.21	1,008.76
(ii) Total outstanding dues of creditors other than micro & small enterprises.	2,007.70	1,569.52
(c) Other current liabilities	2,700.04	564.21
(d) Short term provisions	20.67	69.04
TOTAL	27,315.90	21,187.18
II. ASSETS		
(1) Non- current assets		
(a) Property, plant & equipments & intangible assets		
(i) Property, plant & equipments	8,677.05	7,191.99
(ii) Intangible assets	443.28	443.28
(iii) Capital work in progress	516.47	410.12
(iv) Intangible assets under development	-	-
(b) Non-current investments	4,657.76	1,731.50
(c) Deferred tax assets(net)	-	-
(d) Long -term loans and advances	54.08	76.57
(e) Other non-current assets	423.55	199.77
(2) Current assets		
(a) Current investments	-	1,583.65
(b) Inventories	3,089.80	3,137.07
(c) Trade receivables	6,754.37	4,805.88
(d) Cash and bank balances	1,680.93	620.71
(e) Short-term loans and advances	639.88	937.54
(f) Other current assets	378.73	49.10
TOTAL	27,315.90	21,187.18

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered accountants

Firm registration no. :- 018542C/C400322

Navodit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKOE8591

Place :- Noida

Date :- 14th Nov,2025



For & on behalf of the board of directors

Chandan Healthcare Limited

Amar singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 14th Nov,2025

Asmita singh

Managing director

Din. :- 01098055

Place :- Lucknow

Date :- 14th Nov,2025

Rajeev Nain

CFO & Company secretary

Place :- 14th Nov,2025

Date :- Lucknow

COMPANY NAME :- Chandan Healthcare Limited

CIN :- L85110UP2003PLC193493

REGISTERED ADDRESS :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Consolidated Statement of Cash flow for the half year ended 30th Sept, 2025

Particulars	Figures for the half year ended 30th Sept, 2025	Figures for the year ended 31st March, 2025
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	2,225.54	3,206.52
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	492.90	674.48
Bad Debts & Balances written off/written back	0.92	(124.78)
Re-measurement (gains) / loss on defined benefit plans	(203.00)	84.27
Provision for doubtful debts	(18.56)	15.35
Provision for obsolete inventories	15.21	26.72
Non operating transactions		
Interest on borrowing	279.95	457.53
Interest income	(167.77)	(72.98)
Dividend income	-	-
Operating profit/(loss) before working capital changes	2,625.20	4,267.10
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	32.06	(1,339.42)
(Increase) / Decrease in trade receivables	(1,930.85)	(1,699.38)
(Increase) / Decrease in other current assets	(233.26)	(2,929.24)
(Decrease) / Increase in trade payables	612.63	543.05
(Decrease) / Increase in other current liabilities	2,209.56	(876.75)
Net cash (used in) / generated from operating activities	3,315.33	(2,034.64)
Income taxes refund / (paid), net	(574.79)	(854.92)
Net cash flow from operating activities(A)	2,740.54	(2,889.56)
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(2,084.31)	(3,870.48)
Sale/(Purchase) of non current & current investments	(1,342.61)	222.97
Interest income	167.77	72.98
Dividend income	-	-
Net cash flow from investing activities(B)	(3,259.15)	(3,574.53)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital	-	6,227.11
Proceeds from/(Payment of) long term & short term borrowings	1,858.76	1,225.27
Finance cost paid (including processing fees)	(279.95)	(457.53)
Dividend paid	-	(300.00)
Net cash flow from financing activities(C)	1,578.81	6,694.85
Net increase/decrease in cash or cash equivalents(A+B+C)	1,060.20	230.76
Cash and cash equivalents at the beginning of the period	620.75	389.99
Cash and cash equivalents at the end of the period	1,680.95	620.75

As per our report of even date attached
For M/s Msnt & Associates LLP
Chartered accountants

Navodit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKOE8591

Place :- Noida

Date :- 14th Nov,2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 14th Nov,2025

Rajeev Nain

CFO & Company secretary

Place :- 14th Nov,2025

Date :- Lucknow

Asmita singh

Managing director

Din. :- 01098055

Place :- Lucknow

Date :- 14th Nov,2025



MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

14th November, 2025.

To,
The Manager – Listing Department.
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

Reference: - Chandan Healthcare Limited

NSE Code:-CHANDAN

ISIN: INE0B2N01016

Sub: Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations) for the half year ended on 31st March, 2025.

Dear Sir,

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on 09th October, 2025.

This is for your information and records please.

Please take the above information on record.

Thanking You,

Yours Faithfully



For Chandan Healthcare Limited



: **Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.

: **Branch Office:** - 239, Satra Plaza, Sector-19 D, Palm Beach Road, Vashi, Navi Mumbai-400703.



: **CA Saurabh Tyagi:** 7718802884, **CA Navodit Tyagi:** 9167436404, **CA Manoj Modi:** 9022059201.



: saurabh@msnt.in navodit@msnt.in manoj@msnt.in

Annexure 1-Statement of Deviation or Variation in Utilization of Funds Raised

Name of the Listed Entity	Chandan Healthcare Limited
Mode of Raising Fund	Initial Public Offer
Date of raising Fund	17th Feb, 2025
Amount Raised (Rs. in Lakhs)	7041.94
Report filed for the quarter/half year	30 th September , 2025
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	--
If yes, Date of shareholder approval	--
Explanation for Deviation/Variation	--
Comments of the Audit Committee after review	
Comments of the Auditors, if any	

Objects for which funds have been raised and where there has been a deviation, in the following table:

- Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Jankipuram, Lucknow, Uttar Pradesh.***

Original Object	Modified Object, if any	Original Allocation (Amount in Lakhs)	Modified Allocation, if any	Funds Utilised till 30.09.2025 (Amount in Lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ashiyana, Lucknow, Uttar Pradesh.</i>						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication work	NO	710.11	0	710.11	0	
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ayodhya , Uttar Pradesh.</i>						
Funding capital expenditure towards installation of plant & machinery in our	NO	710.12	0	710.12		



New premises along with required, electric and fabrication work						
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Jankipuram , Lucknow, Uttar Pradesh.</i>						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required civil, electric and fabrication work	NO	3281.58	0	587.267	0	Partially Utilised till September, 2025
General corporate purposes	NO	1672.45	0	1,480.05	0	Partially Utilised till September, 2025
Issue related expenses	NO	670.27	0	670.27	0	

Deviation or variation could mean:

Deviation in the Objects or purposes for which the funds have been raised or

Deviation in the amount of funds actually utilized as against what was originally disclosed or

Change in terms of a contract referred to in the funds raising documents I.e., prospectus, Letter of Offer

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.018542C/C400322

Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 25533375BMOKOG3385

Place: Noida

Date: 14/11/2025

